<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is a group of highly <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> clonal disorders of myeloid hematopoietic stem cells, frequently characterized by bone marrow <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and increased risks of transformation into <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In recent years, several advances have been acquired in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Allogeneic hematopoietic stem cell transplantation is still the only way to make <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> to be long-term remission and even cure </plain></SENT>
<SENT sid="3" pm="."><plain>And as for the use of drug, besides lenalidomide, <z:chebi fb="0" ids="50131">decitabine</z:chebi> and <z:chebi fb="0" ids="2038">azacitidine</z:chebi> approved by FDA, other medicines such as RAP-536, HDAC inhibitor, infliximab and combination therapy have also been used </plain></SENT>
<SENT sid="4" pm="."><plain>This article focuses attention on the recent advances of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> treatment in hope of better understanding the present therapeutic status for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>